June 7th 2021, 12:46am
The study's lead author said researchers have searched for a generation for an effective therapy to give to high-risk patients with renal cell carcinoma after initial surgery for the tumor.
June 6th 2021, 5:52pm
Also, phase 2 results for atezolizumab presented during the 2021 Annual Meeting of the American Society of Clinical Oncology could help patients in same setting who need another option.
June 1st 2021, 9:13pm
On this episode of Managed Care Cast, a research scholar at the Marron Institute of Urban Management at New York University discusses the latest findings in the Health of the Air report, which was presented at the recent American Thoracic Society 2021 International Conference.
May 26th 2021, 6:43pm
Martin J. Edelman, MD, chair of the Department of Hematology/Oncology and associate director for Translational Research at the Fox Chase Cancer Center in Philadelphia, Pennsylvania, discusses the the nuances of rescinded indications in small-cell lung cancer.
May 25th 2021, 9:09pm
Recent coverage from Targeted Oncology® highlights how combination therapies are impacting the treatment spectrum for chronic lymphocytic leukemia (CLL).
May 20th 2021, 1:10pm
Technological innovation is helping to reinvent the traditional health economics and outcomes research (HEOR) field as traditional and new players partner to leverage data sources.
May 19th 2021, 3:10pm
An author of a study in the May 2021 issue of The American Journal of Managed Care® describes how the COVID-19 pandemic, the aging of America, and already-existing workforce shortages will further threaten the dual-eligible population unless policy makers reform scope-of-practice laws.
May 17th 2021, 9:10pm
The COVID-19 pandemic brought together the world and taught health systems how to be resilient and adapt to both predictable and unpredictable changes, said the panelists during the plenary on day 1 of Virtual ISPOR 2021.
May 16th 2021, 7:57pm
Two top cardiologists debated evidence involving one clinical trial for omega-3 fatty acids, with implications for another, the REDUCE-IT study for icosapent ethyl (Vascepa).
May 16th 2021, 12:00pm
The Dapagliflozin in Respiratory Failure in Patients With COVID-19 trial is the first phase 3 study to examine whether this SGLT2 inhibitor, which has proven effective for multiple chronic conditions, might be similarly useful in an acute setting.
